Most Recent Articles about FGEN
https://www.zacks.com/stock/news/2258650/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2258650
Apr 19, 2024 - Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
zc:5119310641520788903
0
https://www.zacks.com/stock/news/2257798/diamedica-dmac-up-as-stroke-study-dosing-begins-post-relaunch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257798
Apr 18, 2024 - DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
zc:8721990482063662535
0
https://www.zacks.com/stock/news/2254517/is-entera-bio-entx-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2254517
Apr 12, 2024 - Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.
zc:7826839061045441053
0